EEG Aperiodic Activity as Biomarker: Implications for Psychiatric Trials

EEG Aperiodic Activity: Findings from a Systematic Review

A systematic review published on October 4, 2026 (OpenAlex W7219852717) evaluated the role of electroencephalography (EEG)-derived aperiodic activity as a biomarker across schizophrenia-spectrum, bipolar, and depressive disorders. The review included 30 studies with a combined sample of 2,298 adult participants, covering cross-sectional, longitudinal, and interventional designs. The main finding is that aperiodic EEG parameters—such as spectral slope and offset—are not stable diagnostic signatures but instead reflect context-sensitive, within-subject markers of cortical state and treatment-related change.

In schizophrenia-spectrum disorders, results were heterogeneous: some studies reported steeper slopes, higher offsets, or reduced temporal flexibility compared to healthy controls, but these findings varied by recording context and study design. For major depressive disorder (MDD) and treatment-resistant depression (TRD), flatter slopes and reduced offsets were more consistently observed, especially in central and posterior brain regions. Bipolar disorder evidence was sparse and methodologically inconsistent, precluding quantitative synthesis. Across diagnoses, task-related and dynamic EEG measures showed greater clinical relevance than static, resting-state parameters.

Mechanistic Context: What Aperiodic EEG Measures Reflect

Aperiodic EEG activity, sometimes called the "1/f" component, is thought to index the balance of excitation and inhibition in cortical networks. Unlike oscillatory (rhythmic) EEG features, aperiodic parameters are not tied to specific frequency bands but rather describe the overall shape of the EEG power spectrum. This review highlights that aperiodic measures are sensitive to brain state, task engagement, and pharmacological interventions, suggesting they reflect dynamic physiological processes rather than fixed disease traits.

Importantly, the review notes that aperiodic parameters often change in response to treatment, but the direction and magnitude of these changes differ by intervention and diagnosis. For example, some antidepressant or neuromodulatory treatments modulated aperiodic slope or offset, but not always in the same way across studies. This variability underscores the need for direct physiological validation—such as concurrent EEG and intracranial recordings—to clarify what these metrics actually represent at the neural circuit level.

Policy and Research Implications for Psychedelic Trials

The review’s findings have direct implications for the design of psychedelic clinical trials and translational studies. EEG is widely used as a noninvasive tool to monitor brain activity in both research and clinical settings, and aperiodic parameters have been proposed as candidate biomarkers of treatment response or neuroplasticity. However, this review cautions that methodological heterogeneity—differences in EEG acquisition, preprocessing, and parameterization—limits the comparability and interpretability of findings across studies.

For psychedelic research, where EEG is often used to probe acute and lasting brain changes, the lack of harmonized protocols and physiological benchmarks poses a risk of false positives or misleading endpoints. The review recommends that future studies adopt standardized EEG protocols, preregistered analysis plans, and, where possible, integrate physiological validation (e.g., animal models or intracranial data) to ensure that aperiodic measures are robust and meaningful. This is especially salient as regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) increasingly scrutinize the validity of proposed biomarkers in psychiatric drug development.

Risks, Unknowns, and Failure Modes

EEG aperiodic activity is not yet a validated or regulatory-accepted biomarker for psychiatric diagnosis or treatment response. The review identifies several risks and unknowns: methodological inconsistency, lack of disorder specificity, and unclear physiological meaning. For instance, aperiodic parameters can be influenced by non-neural factors such as muscle activity, electrode placement, and preprocessing choices—potentially confounding results. Moreover, the review notes that treatment-related changes in aperiodic measures may not track with clinical improvement, raising questions about their utility as surrogate endpoints.

A non-obvious failure mode surfaced in this review is the risk of over-interpreting group-level differences as stable biomarkers, when in fact these measures may be more useful for tracking within-subject changes over time or in response to interventions. This distinction is crucial for designing trials that aim to personalize psychiatric care or monitor neurobiological effects of psychedelics and other novel treatments.

Looking Forward: Harmonization and Validation Needed

Future research must prioritize methodological harmonization and physiological validation of EEG aperiodic measures before they can be reliably integrated into clinical trials or practice. This includes consensus on data acquisition, analysis pipelines, and reporting standards, as well as direct studies linking EEG aperiodic activity to underlying neural mechanisms. For psychedelic research, the field should focus on within-subject designs, dynamic task paradigms, and multimodal validation to maximize the interpretability and translational value of EEG endpoints.

As the use of EEG in psychiatric and psychedelic research expands, stakeholders—including investigators, sponsors, and regulators—should remain cautious about adopting aperiodic parameters as primary or secondary endpoints until their reliability and clinical relevance are firmly established. The path forward will require coordinated efforts across disciplines, transparent reporting, and ongoing dialogue with regulatory bodies to ensure that advances in neurophysiology translate into meaningful clinical innovation.

By Dr. Alex M. Stein, PhD (Neuroscience). How we research: All claims are based on direct review of the cited systematic review (OpenAlex W7219852717) and primary regulatory guidance. Reviewed by Dr. Alex M. Stein on 2026-10-06.